20 May 2026

MedPal AI plc

("MedPal AI" or the "Company")

Launch of New Health on new.co.uk as dedicated GLP-1 and peptides brand

New Health to operate as a specialist consumer brand within MedPal AI, positioned for GLP-1 growth and the expected UK oral GLP-1 step-change

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy platform, is pleased to announce the launch of New Health, a dedicated consumer sub-brand focused on the GLP-1 weight-management and broader peptide medicines market opportunity, supported by a £1.3 million national consumer marketing campaign. The launch is being positioned in the context of rapid growth in the GLP-1 category and ahead of the Board's anticipated UK approval of Novo Nordisk's once-daily weight-management pill in summer 2026.

New Health will sit separately from the broader MedPal Clinic app and MedPal consumer platform. It has been created to give the Company a sharper consumer brand, acquisition funnel and patient journey for the highly competitive GLP-1 category, while continuing to use MedPal AI's regulated healthcare infrastructure comprising: AI-assisted intake, clinician-led assessment, prescribing where clinically appropriate, automated pharmacy dispensing and ongoing monitoring.

Highlights

·      New Health launched as a specialist sub-brand of MedPal AI focused initially on GLP-1 weight management and, over time, the broader peptides opportunity.

·      The sub-brand will operate separately from the MedPal Clinic app to allow a dedicated consumer proposition in a competitive, brand-led market, while remaining fully connected to MedPal AI's clinical, pharmacy and technology infrastructure.

·      £1.3 million has been committed to a national consumer marketing programme, with performance-led digital activity expected to be a principal component.

·      Marketing campaign is designed to drive traffic to websites new.co.uk and new.uk, to increase initiations of qualified consultations and to grow the New Health recurring patient base.

·      Market context supported by published research indicating significant UK and global GLP-1 growth, including forecast UK prescription weight-loss medication market growth at a CAGR of approximately 25% from 2026 to 2033.

·      The Board anticipates that the potential UK approval of Novo Nordisk's oral Wegovy pill this summer could broaden the addressable market by attracting patients who may not previously have considered injection-based treatment.

·      New Health will be underpinned by MedPal AI's NHS-contracted dispensing hubs in Runcorn and Swaffham, Distance Selling Pharmacy licences, direct supply agreements with Eli Lilly and Novo Nordisk for current GLP-1 medicines, and an AI layer built on Google Vertex AI.

Strategic rationale: a focused sub-brand for a competitive market

The Board believes that the private GLP-1 weight-management market has become one of the most competitive areas of consumer healthcare, with patients comparing providers on the basis of brand trust, ease of access, clinical governance, price, prescription fulfilment and ongoing support. In this environment, the Board believes a specialist consumer brand is required to compete effectively with established online weight-management providers and pharmacy-led entrants.

New Health has, therefore, been created as a focused GLP-1 and peptides sub-brand within MedPal AI, with its own consumer positioning, website, campaign messaging and acquisition funnel. The purpose is not to replace the MedPal Clinic app, but to sit alongside it. New Health provides a specialist consumer entry point for this category, while the wider MedPal platform remains the Company's health operating system and regulated care infrastructure.

The Board believes this structure will allow MedPal AI to better compete at the same level as dedicated consumer brands in the GLP-1 market, while retaining the advantages of owned pharmacy infrastructure, human clinical oversight, AI-assisted patient engagement and longitudinal monitoring.

Market context: GLP-1 growth and oral pill opportunity

The Board notes published market research indicating that the GLP-1 category is expanding rapidly. Morgan Stanley Research has forecast that the global market for GLP-1 treatments could reach approximately £140 billion by 2035, more than double reported 2025 levels. In the UK, Grand View Research estimates that the UK prescription weight-loss medications market was approximately £313 million in 2025 and is projected to reach approximately £1.85 billion by 2033, representing a compound annual growth rate of approximately 25% from 2026 to 2033.

IQVIA evidence submitted to the UK Parliament also points to rapid private-market growth, indicating that more than 2.37 million UK citizens had access to GLP-1s in July 2025, of which approximately 200,000 accessed treatment through the NHS. The Board believes this market backdrop supports New Health operating as a distinct, focused MedPal AI sub-brand for GLP-1 and peptide-led services.

The Board anticipates that Novo Nordisk's once-daily oral semaglutide 25 mg weight-management pill, approved by the FDA in December 2025 and submitted to the EMA and other regulatory authorities during the second half of 2025, could receive UK approval during summer 2026. The Board believes that a pill-based GLP-1 option could bring a new cohort of customers into the market, including patients who may be reluctant to start injection-based treatment. There can be no certainty as to UK regulatory approval, timing, supply, clinical availability or prescribing requirements.

Marketing and patient acquisition

The £1.3 million marketing programme is intended to establish New Health as a recognised consumer entry point for eligible patients seeking regulated weight-management support. Target audiences will include UK adults actively researching weight-loss support, GLP-1 treatment options, obesity and metabolic health, as well as consumers who may become interested in tablet-based or other peptide-led treatment options as and when they are approved and clinically available in the UK. The Board expects oral GLP-1 availability, if approved, to broaden the top of the acquisition funnel and bring a new cohort of customers into the category.

The marketing spend is expected to be phased over six months and performance-led, with digital channels such as Google expected to be a principal component. Management will monitor traffic to new.co.uk, initial consultations, completed clinical assessments, conversion to new patient sign-ups, retention, customer acquisition cost and gross contribution, with the ability to increase, reduce or reallocate spend according to unit economics, patient-safety requirements and clinical/pharmacy capacity.

All New Health services and communications will be delivered subject to clinical eligibility, medicine availability, appropriate clinician review, prescription-only medicine rules and all applicable UK pharmacy, clinical governance and advertising requirements.

Related party Transaction

CEO Jason Drummond, owns the domain names new.co.uk and new.uk and has agreed to licence them to the Company for nil consideration for an initial period of six months. The provision of the domain licences constitutes a related party transaction for the purposes of AIM Rule 13. The directors of the Company, with the exception of Jason Drummond, having consulted with Cairn Financial Advisers LLP, the Company's nominated adviser, consider that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned.

At the end of six months, the Company will have the option to acquire the domain names.

Commenting on the launch, Jason Drummond, Founder and Chief Executive Officer of MedPal AI plc, said:

"New Health is a focused sub-brand within MedPal AI for a specific opportunity: GLP-1 weight management and the broader peptides category. This market is highly competitive and brand-led, so we need a consumer proposition that can compete on the same terms - a simple brand, a clear message, a dedicated funnel and strong clinical governance behind it.

"MedPal AI remains the operating system for personal health. New Health is the specialist point of access for patients seeking GLP-1 weight-management support and, over time, broader peptide-led healthcare services where clinically appropriate. The patient sees a clear consumer brand; behind it sits MedPal's AI-assisted intake, clinicians, prescribing pathway, pharmacy fulfilment and monitoring.

"Our £1.3 million marketing investment is designed to build New Health as a scalable consumer channel, not as generic corporate advertising. The market data supports the timing: published research points to rapid UK and global growth in prescription weight-management medicines, and the Board anticipates that the expected UK approval of Novo Nordisk's oral Wegovy pill this summer could bring a new cohort of patients into the category. We will monitor traffic, conversion, customer acquisition cost, retention and gross contribution in real time and will scale spend only where the unit economics, governance and capacity support it.

Watch an interview with Jason Drummond on the subject of the new brand at this link:

https://www.youtube.com/watch?app=desktop&v=HjejrjlRG5Y&pp=iggCQAE%3D&ra=m

Ends

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries

About MedPal AI plc

MedPal AI plc (AIM: MPAL; FRA: Z1N) is a UK-listed AI-native digital health and pharmacy platform. The Company operates automated NHS-contracted dispensing hubs in Runcorn and Swaffham and holds Distance Selling Pharmacy licences. Its MedPal Clinic app and broader platform connect AI-assisted patient engagement, clinical services and automated pharmacy fulfilment. New Health is the Company's dedicated consumer sub-brand for GLP-1 weight management and the broader peptide medicines opportunity. MedPal AI has direct supply agreements with Eli Lilly and Novo Nordisk for current GLP-1 medicines. The Company's AI layer runs on Google Vertex AI and supports patients through WhatsApp and the MedPal consumer app.

Forward-looking statements

This announcement contains certain forward-looking statements, including statements regarding the Company's strategy, expected market developments, anticipated UK regulatory approval, timing and clinical availability of Novo Nordisk's once-daily oral semaglutide 25 mg weight-management tablet, consumer adoption, marketing activity, patient acquisition, customer acquisition cost, return on marketing investment, the expected benefits of the New Health sub-brand and future peptide medicines opportunities. Forward-looking statements are based on current expectations and assumptions and are subject to risks, uncertainties and other factors which may cause actual results, performance or developments to differ materially. Market and industry data cited in this announcement has been sourced from publicly available third-party reports and has not been independently verified by the Company. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law or regulation.